About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Prostate Cancer Clinical Trials in Nashville | 305 Studies

Clinical Trials Prostate CancerNashville

Prostate Cancer Clinical Trials in Nashville

Find 305 clinical trials for prostate cancer near Nashville, Tennessee. Connect with research centers in your area.

All Prostate Cancer trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 61-80 of 305 trials

TerminatedA Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate CarcinomaThis is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects…NCT04740034·San Francisco, California and 6 others RecruitingA Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerThis study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy…NCT07365995·Santa Barbara, California and 32 others

Prostate Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedImmune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-TThe purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).NCT01727154·Scottsdale, Arizona and 38 others

Active not recruitingSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsThe intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic…NCT06120491·Chandler, Arizona and 321 others

RecruitingA First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced…NCT07488923·St Louis, Missouri and 5 others

RecruitingStudy of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid TumorsThis Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx)…NCT06545942·Goodyear, Arizona and 17 others

CompletedStudy of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration…NCT04179396·Atlanta, Georgia and 2 others

Active not recruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple…NCT02465060·Birmingham, Alabama and 1409 others

TerminatedA Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous…NCT05489991·Nashville, Tennessee

CompletedCP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate CancerThis is a multi-center, open label, randomized study.NCT00075192·La Masa, California and 10 others

CompletedPSA Vaccine Therapy in Treating Patients With Advanced Prostate CancerRATIONALE: Vaccines may make the body build an immune response to kill tumor cells.NCT00003871·Indianapolis, Indiana and 9 others

WithdrawnCabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With DocetaxelAlthough there have been advances in the treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC), all patients eventually develop resistance to available…NCT02035124·Fort Myers, Florida and 2 others

CompletedEfficacy Study of ABR-215050 to Treat Prostate CancerTo investigate ABR-215050 as a possible treatment for prostate cancer.NCT00560482·Anchorage, Alaska and 64 others

RecruitingStudy of PF-07248144 in Advanced or Metastatic Solid TumorsThis is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of…NCT04606446·Scottsdale, Arizona and 43 others

Active not recruitingA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with…NCT04471727·Los Angeles, California and 10 others

Active not recruitingAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or…NCT02257736·Phoenix, Arizona and 172 others

RecruitingA Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers.NCT06440005·Los Angeles, California and 6 others

CompletedOpen- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerThe ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer…NCT03686683·Gilbert, Arizona and 55 others

CompletedRadiation Therapy in Treating Patients With Stage II or Stage III Prostate CancerRATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.NCT00002602·Birmingham, Alabama and 227 others

RecruitingMetastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TA multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).NCT06134232·Tuscon, Arizona and 30 others

PreviousPage 4 of 16Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Colorectal Cancer Melanoma Leukemia Lymphoma